SystemRegulatory Affairs

Regulatory Intelligence

Regulatory intelligence software that tells each team what an agency change means for its products

See one case, screen by screen ↓
Watch with transcript →

Built forRegulatory intelligence leadsProduct regulatory leadsAffiliate labeling teamsDevice engineers

The Problem Today

Agency updates are found, translated and compared by hand, so the product team a change lands on learns of it late.

Found and read by hand

  • Bookmarks
  • Alerts
  • Newsletters
  • PDFs
  • Findings buried in emailThe side-by-side comparison sits in one person's inbox
  • A new expectation missed at filingThe variation goes in without the data the assessor expects

The Solution

  1. Each agency source checked at dawnNew or changed guidance and notices collected, duplicates dropped
  2. Translated and summarizedJapanese, Chinese, German and more, in three to five plain lines
  3. Compared with the text it replacesParagraph by paragraph, each change named with the team it lands on
  4. A lead signs the impactHigh and Medium impacts per product, signed before any team is told

Built-in controls

  • Each summary line cites its passage
  • The original wording kept beside its translation
  • Low impacts filed, with a weekly sample reviewed

What You Get

A signed impact per product and market, with the passages behind it, so filing plans are set against the new text.

  • Proposed impacts with reasonsPer product and market, with the agent's confidence shown
  • Affiliates hear the same dayEach team gets its own paragraphs in its own language
  • Answers in any languageAsk a question and get the passage, translated and cited
In short

What is Regulatory Intelligence?

Regulatory intelligence software watches health authorities for new and changed guidance, regulations and safety communications and tells regulatory affairs what each one means for its products. Regulatory Intelligence adds seven agents that check 64 sources each morning, translate, summarize with citations, compare revised documents with the versions they replace and propose the impact per product, for a regulatory lead to confirm and sign.

How to choose AI solutions for life sciences →

Updated

The problem

An agency change can take a week to reach the team it lands on

Regulatory teams read hundreds of agency pages a week in a dozen languages: FDA guidance and Federal Register notices, EMA guidelines and CHMP outcomes, PMDA and MHLW notices in Japanese, NMPA announcements in Chinese, ANVISA resolutions in Portuguese. Most of it arrives as PDFs, found through bookmarks, email alerts and newsletters, then copied into a spreadsheet.

A revised guideline rarely says what it changed. Someone puts the draft beside the version it replaces and compares them by hand, the finding lives in an email, and the product regulatory lead hears about it a week later. A notice in Japanese waits for translation while its deadline runs. Miss one paragraph and a variation goes in without the data the assessor now expects.

Where an agency change's days go before its team hearsestimated
By hand7.6 days
With the solution0.1 days
  • Spotting it across agency sites, alerts and newsletters1.6 → 0.0 d
  • Waiting for a translation of a notice not in English1.5 → 0.0 d
  • Reading, summarizing and logging it1.2 → 0.0 d
  • Comparing a revised text with the version it replaces1 → 0.0 d
  • Deciding the impact per product and who owns it1.3 → 0.1 d
  • Sign-off and telling the owning team1 → 0.1 d

Estimated split for one update, by hand and with the solution. The totals match the median on the working solution's dashboard: 7.6 days by hand in 2025, 3.4 hours with the agents.

How it works

From agency page to signed impact: the regulatory change monitoring flow

What comes in
Agencies watched64 sources · 38 countries, any language
Agents at work
Agency watchernew and changed only
Then
Translatorwhen not in English
Then
Summarizercited summary
Then
Version comparerold vs new wording
Then
Impact assessorper product, per market
A person decides
Regulatory leadconfirms each impact
What comes out
Morning front page
Each team told
Cited answers
One case, step by step

Regulatory intelligence on one morning: a revised EMA draft and a PMDA notice

One weekday morning in the sample. Overnight, EMA published a revised drug–device quality guideline for consultation, and PMDA, FDA and NMPA each issued something that touches four products in the portfolio, among them a biologic, a stent and a glucose monitor. Here is what happens next, screen by screen, in the working solution.

A worked example on sample data. Names, IDs and figures on the screens and in this section come from the demo.

  1. 0105:00 to 05:12 CET

    Sixty-four sources checked before anyone is at a desk

    The agents

    The agency watcher checks 64 sources in 38 countries and finds 41 changed pages, 27 new updates once duplicates are removed. The translator renders 9 documents from Japanese, Chinese, German and Portuguese, originals kept. The version comparer checks 3 revised documents against the versions they replace: 22 changed paragraphs, 5 of which change a plan. The impact assessor proposes 5 High, 8 Medium, 10 Low and 4 not relevant.

    “Chose the lead: highest impact on your products. EMA drug–device draft · the biologic's autoinjector.” 05:12

  2. 02Morning

    The Regulatory Morning, led by the update that matters most to the portfolio

    Regulatory intelligence lead

    The edition printed at 05:12 CET: 27 updates, 9 agencies, 64 sources checked. The lead story is EMA's draft revision of the drug–device quality guideline, which puts the biologic's switch to an autoinjector in scope. Beside it: a labeling format change for the biologic with two deadlines on the same day, the edition's deadlines, and 13 High and Medium impacts waiting for a signature. Below, a column each for FDA, EMA, PMDA / MHLW, NMPA and MHRA.

    “High and Medium impacts. Teams are told only after a lead signs.”

  3. 03What changed

    Two of eleven changed paragraphs change the plan

    Version comparer

    Against the 2019 guideline in force, 11 paragraphs changed: 6 editorial, 3 that need a check and 2 that change the plans. §4.2 is rewritten: a variation that changes the device part of an integral product now needs comparability data and a Notified Body Opinion, which lands on the biologics regulatory lead. §4.3 is new: moving from prefilled syringe to autoinjector needs delivered-dose, dose-accuracy and injection-time comparability on three batches, which lands on device engineering.

    The comparer works against the version the agency names as replaced, word for word.

  4. 04Sign

    The lead confirms the impact, with the meaning of the signature

    Regulatory intelligence lead

    The plan view shows three new steps for the autoinjector's EU variation: book the notified body, the notified body opinion, and two more delivered-dose batches over the winter. The planned filing month holds only if the notified body is booked by a set date. The lead confirms the autoinjector as High and the prefilled syringe as Medium, leaves the three teams ticked to be notified and signs: “I confirm this impact assessment”.

    “Signed electronically: your name, date, time and meaning go on the audit trail.”

  5. 0509:14 CET

    Each team gets its exact paragraphs that morning

    Digest writer

    The impact is confirmed at 09:14. Biologics regulatory gets §4.2, Device engineering gets §4.3, §5.3 and §6, and Regulatory policy gets §8, each note with the original document attached. Nothing was sent before the signature.

    “Impact confirmed · Biologics regulatory, Device engineering and Regulatory policy notified”

  6. 06The second lead

    A Japanese notice, read beside its translation

    Translator and Summarizer

    An MHLW notice puts the biologic in the first wave of XML format 2.0 for electronic package inserts: each section goes into structured fields, and the re-issued insert must be on the PMDA website by a set date. Each paragraph of the original sits next to its English translation, and each summary line links to its passage. The impact assessor proposes High for Japan, 95% confident.

    “The labeling plan puts the Japan label update in a later cycle. The notice requires posting about 10 weeks earlier.”

  7. 07One question

    “Does the new PMDA notice change our labeling timeline?”

    Regulatory intelligence lead

    The assistant searches 4,812 updates and 3 internal plans, reads the notice in Japanese and checks the labeling plan. Yes: it moves the Japan label update for the biologic forward by about 10 weeks, and the EU asks for the same product information in the ePI standard, due the same day. The sources open beside the answer: the Japanese passage highlighted with its translation, and the Japan row of the labeling plan.

    “Next step: open a Japan label change now and add the wording to the core data sheet, so both markets move together.”

  8. 08All 27

    The rest of the edition behind the front page, in one list

    Regulatory intelligence lead

    The other updates sit in one list: 5 High, 8 Medium, 10 Low, 4 not relevant, filterable by agency and product and searchable in any language, translated titles beside the original. Each row carries its deadline: comments close on the EMA draft in 117 days, and comments on the FDA stent draft are due by year end.

  9. 09Across the portfolio

    Open impacts by product and agency

    Devices regulatory lead

    The impact board lays the open impacts out by product and agency, then by stage: 13 new and waiting for confirmation, 3 assessed with teams working, 4 actioned. The stent carries three FDA impacts, led by the revised stent draft that asks for five years of follow-up where the PMA supplement plans three. Fourteen Low and Not relevant updates were filed automatically today.

  10. 10This year

    Within hours of publication, where it used to take a week

    Regulatory intelligence lead

    The dashboard shows 3,977 updates read this year from 64 sources in 38 countries, and a median of 3.4 hours from publication to the owning team, against 7.6 days by hand the year before. 714 High and Medium impacts were confirmed this year, each signed by a named lead; 96% were confirmed within 2 working days, and leads kept the agent's proposed impact 91% of the time.

    “Each High and Medium impact this year was confirmed by a named lead before teams were notified.”

Who it’s for

Regulatory intelligence for the lead, product, device and affiliate teams

Five people an agency change reaches: how their week went by hand, and how it goes now.

Regulatory intelligence lead
Confirms each impact
Before
Reads the overnight agency output, decides who must know and chases the owners by email, looking for the one update that moves a filing.
Now
Opens a front page led by the update that moves a filing, reads the two paragraphs that matter and signs; the teams are told that morning.
Biologics regulatory lead
Owns the biologic in all markets
Before
Owns the biologic's EU variations and the filing calendar, and wants the two paragraphs that changed without rereading the whole guideline.
Now
Gets §4.2 old and new, side by side, with the effect on the autoinjector variation plan and the date the notified body must be booked.
Device engineer
Owns delivered-dose data
Before
Hears about new data expectations late, and needs to know which batch data is missing and by when.
Now
Receives §4.3 with the gap named: delivered-dose data from one engineering batch, two more needed before Module 3 is written, over the winter.
Japan affiliate labeling lead
Confirms PMDA and MHLW updates
Before
Turns MHLW notices, written in Japanese and carrying firm deadlines, into package insert changes.
Now
Sees the notice beside its translation, the posting date against the labeling plan, and the EU ePI variation due the same day.
Devices regulatory lead
Owns the stent and glucose monitor
Before
Tracks the stent and the glucose monitor across FDA, NMPA, MHRA and PMDA, where five years of follow-up instead of three changes the PMA plan.
Now
Sees each open impact on the stent and the glucose monitor by agency, and confirms the ones for these products.
The agents

Watcher, translator, comparer and assessor: the agents in each morning run

Agency pages are watched, translated and compared with the versions they replace, and each update is assessed per product; a regulatory lead signs the impact.

Agency watcher

Checks 64 agency sources each morning from 05:00 CET for new or changed guidance, notices, regulations and safety communications, keeping the original file, its address and publication date, and dropping duplicates.

  • Reads only the approved source list
  • Keeps the original file and its web address
  • Never signs in to agency portals
Translator

Translates Japanese, Chinese, German, Portuguese, French, Korean and more into English, paragraph by paragraph, with the original side by side.

  • The original text is always kept
  • Regulated terms come from the glossary
  • Flags passages it is unsure of
Summarizer

Writes three to five plain lines per update (what changed, for which products or devices, and by when) and records the key dates: published, comments close, effective.

  • Every line cites a passage
  • No advice: facts from the source only
Version comparer

When a guideline is revised, finds the version it replaces, compares them paragraph by paragraph (rewritten, new, widened or editorial) and names the team and plan each change lands on.

  • Compares against the version the agency names as replaced, never a guess
  • Shows the old and new wording word for word
  • Proposes the affected team; a lead confirms
Impact assessor

Compares each update with the portfolio register's products and market licenses, the labeling plan and the submission calendar, and proposes High, Medium, Low or Not relevant per product, with the reason and its confidence.

  • Proposes only; a named lead confirms High and Medium
  • Cites the passage behind every reason
  • Impact rules set the minimum level
Digest writer

Lays out the morning front page, led by the update with the highest impact on your products, and sends each team its note in its own language once a lead confirms.

  • Sends only confirmed impacts
  • Original documents attached
Regulatory assistant

Answers questions in any language across all updates and internal plans, citing the exact page for each statement, with the original passage and its translation when the source is not in English.

  • Answers only from sources it can cite
  • Says so when nothing answers the question
Regulatory lead

Confirms each impact.

Ask in plain words

Cited answers on agency updates, in English, Japanese, Chinese or German

Ask in any language, and choose an answer in English, Japanese, Chinese or German. Answers come from 4,812 agency updates and your internal plans, each line linked to the exact page with the original text and a translation. These answers use the sample data.

Does the new PMDA notice change our labeling timeline?

Yes. It moves the Japan label update for the biologic forward by about 10 weeks. The notice puts the product in the first wave of XML format 2.0, and the re-issued electronic package insert must be on the PMDA website by a set date. Your labeling plan has it in a later cycle, and the EU wants the same product information in the ePI standard the same day.

What changed in the EMA drug–device guideline?

11 paragraphs changed against the 2019 guideline, and two change your plans. §4.2 asks for a Notified Body Opinion and comparability data when a variation changes the device part; new §4.3 asks for delivered-dose comparability on three batches when moving from syringe to autoinjector. Both land on the planned autoinjector variation, and the notified body has to be booked first.

Which updates this week affect the stent?

Four, one of them High. FDA's revised draft guidance asks for 5-year follow-up in pivotal trials, where your PMA supplement plans 3 years. NMPA self-test reports for Class III devices will need calibration certificates, and NMPA's draft stent guideline accepts overseas data with at least 15% Chinese patients. MHRA registrations of Class IIb and III devices must be renewed yearly.

中国的哪些新规定影响我们的产品?

Answered in Chinese, with an English line beneath: two NMPA rules affect the stent this week, calibration certificates for self-test reports and at least 15% Chinese patients in overseas data under the draft stent guideline.

The screens

The morning front page, the version comparison and the impact board

From the working solution, on its sample data. Pick one to see it large.

The morning front pageThe lead story with what changed for you, the second lead, this edition's deadlines, impacts awaiting a signature and a column per agency.
The edition printingThe 05:00 to 05:12 run: sources checked, changed pages found, documents translated and compared, impact proposed, the lead chosen.
What changed for youOld and new wording side by side, filtered to the paragraphs that change your plans, with the team each lands on and the filing plan before and after.
Confirm the impactThe impact per product and market, the teams to notify, and the meaning of the signature.
Signed and sentConfirmed by the lead, with the time, and the teams told, each with its own paragraphs.
One update, original and translationA Japanese notice beside its translation, the cited summary and the impact per product with confidence.
Ask in any languageA cited answer with the source passages: the original with its translation, and the internal plan row.
All updatesThe updates behind the front page, by impact, agency, product, stage and deadline, searchable in any language.
The impact boardOpen impacts by product and agency, and where each one stands: new, assessed, actioned.
Past editionsEach morning's front page as printed: the lead story, what it changed and who signed.
The dashboardUpdates read, hours saved, time from publication to the owning team, and how quickly leads confirm.
Your settingsPrint time, lead-story rule, agency columns, version comparison and the watched sources, then approvers, impact rules, the digest and the portfolio register.
Governance

Citations, translations and signatures in regulatory intelligence software

Each line cites its passageEach summary line and impact reason links to its passage, so a reviewer checks the source rather than the summary.
The original beside each translationThe original text stays next to its translation, regulated terms come from the glossary, and unsure passages are flagged.
The agency's own wording, word for wordA revised document is compared only with the version the agency names as replaced, old and new wording shown word for word.
A named lead signs before teams are toldEach High and Medium impact is confirmed by a named lead with an electronic signature that records name, date, time and meaning. The digest sends only confirmed impacts.
Low impact filed, and sampledLow and Not relevant updates are filed automatically, and 10% are sampled for review each week. Impact rules set the minimum level the assessor may propose.
Public sources, each step on the recordThe agents read public agency websites only, with no logins. Each agent step, signature and message to a team is on the audit trail.
Configuration

Regulatory intelligence settings: print time, approvers and impact rules

How the edition is laid out, what the agents watch, who confirms and how teams hear are settings. A changed rule applies from the next morning's run.

SettingDefaultChoose from
Print time05:00 CET check · prints about 05:1204:00 · 05:00 · 06:00 CET check
Lead storyHighest impact, then nearest deadlineHighest impact, then nearest deadline · Nearest deadline first
Agency columnsFDA · EMA · PMDA · NMPA · MHRAFive columns; every other agency goes under “Also in this edition”
Compare revised documentsOnOn · Off
Who confirms impacts — BiologicsBiologics regulatory leadA named approver per product area: Biologics, Small molecules, Devices, Japan, Cross-product and policy
Any labeling change for a marketed productAt least HighHigh · Medium · Low
Daily digest send time07:00 local time06:00 · 07:00 · 08:00 local time
Digest languageTeam's own languageTeam's own language · English for everyone
Connections

Agency sites, the portfolio register, and the labeling and filing plans

Agency websitesFDA, EMA, PMDA / MHLW, NMPA, MHRA, Health Canada, TGA, Swissmedic, ANVISA, the European Commission and 54 more sources
Earlier versionsthe guideline or guidance a revision replaces, from the agency site or the archive
Product portfolio registerevery product, presentation and market license, with its owning team
Labeling planplanned label changes by market and cycle
Submission calendarplanned variations, supplements and filings
Email and chateach team's digest, in its own language, with the original attached
What it changes

Regulatory intelligence software results: hours from publication to team

Each figure carries its label: a target the solution is built to, an estimate, a typical published result, or a proven one.

proven
4,000hours
saved a year in a live deployment
target
3.4hours
from publication to the owning team
By hand7.6 days
With agents≈ 3.4 hours
target
64sources
in 38 countries checked every morning, in any language
sources checked every morning

“demo” = seen in the working solution, on its sample data · “target” = the design goal, measured in the live solution · “estimated” = our estimate. The products, the EMA draft revision and ePI notice, and the PMDA / MHLW, FDA and NMPA notices in the worked example are sample data, modeled on real document forms. Names on the screens are sample data.

Questions

Regulatory intelligence software questions from regulatory affairs teams

What is regulatory intelligence software?

Regulatory intelligence software watches health authorities for new and changed guidance, regulations and safety communications and tells regulatory affairs what each one means for its products. Regulatory Intelligence adds seven agents that check 64 sources each morning, translate, summarize with citations, compare revised documents with the versions they replace and propose the impact per product, for a regulatory lead to confirm and sign.

How does it show what a revised guideline changed?

The version comparer finds the version the agency names as replaced and compares the two paragraph by paragraph: rewritten, new, widened or editorial. It shows old and new wording word for word, filtered to the changes that affect your plans, with the team and plan each lands on.

Does it monitor agencies that publish in other languages?

Yes. Sources include PMDA / MHLW in Japanese, NMPA in Chinese, Swissmedic in German and French, and ANVISA in Portuguese. The original stays next to each translated paragraph, regulated terms come from a glossary, and teams can read their digest in their own language.

How does it decide the impact on our products?

The impact assessor compares each update with the product portfolio register, the labeling plan and the submission calendar, and proposes High, Medium, Low or Not relevant per product and market, with a reason, the passage behind it and its confidence. Impact rules you set (for example, any labeling change for a marketed product is at least High) set the minimum.

Can a team be told about an impact before a lead signs it?

No. The agents propose and never confirm. A named lead signs each High and Medium impact, recording name, date, time and meaning, before any team is told. Low and Not relevant updates are filed automatically, with 10% sampled for review each week.

Can we add our own sources and approvers?

Yes. Watched sources, their schedule, the approver for each product area, impact rules, the print time, the agency columns on the front page and the digest's time and language are all settings. A changed rule applies from the next morning's run.

Can we ask questions about the updates?

Yes. The assistant answers in English, Japanese, Chinese or German from the agency updates and your internal plans, and each line links to the exact page with the original passage and its translation. When nothing answers the question, it says so.

What does regulatory affairs hand over to get started?

Your product portfolio register, labeling plan, submission calendar and the list of agencies you file with. The Agentic Solution Engine builds and deploys it from those requirements and documents, and it goes live once each quality gate has passed. We will walk you through it on your own portfolio first.

Run regulatory intelligence
on your own portfolio.

We'll run Regulatory Intelligence on your own products and the agencies you file with.